Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4066708 · 1 trial · 2 indications
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Part A Cohort 1: Single-Ascending Dose (SAD)- LY4066708 | EXPERIMENTAL | LY4066708 administered by intravenous (IV) injection |
| Part A Cohort 2: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 3A: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by subcutaneous (SC) injection |
| Part A Cohort 3B: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by SC injection |
| Part A Cohort 4: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 5: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 5A: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 6A: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 6: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 1: Multiple-Ascending Dose (MAD)- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 2: MAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 3: MAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 4: MAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Placebo | PLACEBO_COMPARATOR | Placebo administered by IV injection |
| Placebo- Part A Cohort 3A and Part A Cohort 3B. | PLACEBO_COMPARATOR | Placebo administered by SC injection |
| Name | Type | Description |
|---|---|---|
| LY4066708 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Japanese Participants Only: To qualify as a participant of first-generation Japanese origin, the participant, the participant's ...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LY4066708 is an investigational small molecule being developed by Eli Lilly and Company for cancer. It is in Phase 1 clinical development and has not been approved by the FDA. The program is in early testing, with one active trial currently recruiting participants.
LY4066708 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 program evaluating the compound in healthy participants and cancer.
LY4066708 is in Phase 1 clinical development. It is an investigational small molecule and is not FDA approved. The single registered trial is a Phase 1 study that is currently recruiting, with no completed trials reported for the program.
LY4066708 is being studied in one Phase 1 trial, NCT07046559, titled a single- and multiple-ascending dose study to evaluate safety, tolerability, and pharmacokinetics in healthy participants. The trial is recruiting in the United Kingdom, plans to enroll 104 participants, and includes healthy volunteers aged 18 years and older.
The LY4066708 Phase 1 trial NCT07046559 is a randomized, double-blind, placebo-controlled study. It uses single- and multiple-ascending dose designs to assess safety, tolerability, and pharmacokinetics in healthy participants. The study is recruiting in the United Kingdom and has a planned enrollment of 104 participants.